Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As you will see on the next slide, filled prescriptions continue to grow week-over-week throughout Q3 2023, with an acceleration in the last few weeks of the quarter |
| To the point that Tom made, we're very encouraged that the demand is there |
| I remain remarkably encouraged and I'm very pleased that Tom Garner has chosen to join us as we make efforts to accelerate this launch in 2024 |
| Encouragingly, we have been seeing increasing prescription demand and clinical utilization for INPEFA and notwithstanding limited access, are now starting to see major formulary wins, with some of the more notable becoming effective on November 1 |
| With INPEFA significant clinical share of voice and publications and medical meetings, coupled with additional expected formulary wins an increasing uptake from a broadening base of priority physicians, we are confident the momentum behind INPEFA will continue to accelerate as we enter 2024 |
| So encouragingly, we're seeing usage from across the country, both in larger academic institutions but also within the community setting as well, which I think, again, talks to the value of the INPEFA clinical stories that we're able to share and the fact that our clinicians really do understand the differentiated profile that we have in this specific population |
| We have been encouraged to see the growing clinical demand data outpacing our full prescription data by a ratio of nearly five to one |
| We're pleased by the positive reception given by the clinical community to INPEFA as the only SGLT-1/2 inhibitor, indicated for the treatment of heart failure |
| Starting with heart failure market dynamics, the updated treatment guidelines and growing clinical evidence continue to help fuel the growth of heart failure indicated SGLT inhibitors for that indication |
| Importantly, we are seeing meaningful increases in INPEFA demand, as evidenced by submitting claims data that has outpaced filled prescriptions, which is expected as formula access continues to build |
| Even with this significant momentum, the utilization of SGLT inhibitors for the treatment of heart failure was only around 10% last year, providing tremendous opportunity for a new treatment like INPEFA, which has compelling and differentiated data in this specific patient population |
| We are encouraged by the momentum that we are building on both of these fronts |
| It's worth noting that as we close out the first full quarter of our commercial launch, we have seen an acceleration in our prescription data, reflecting improving access conditions for INPEFA |
| Finally, importantly, Lexicon is in a strong cash position with the ability to fund operations well into 2025 |
| So that's very encouraging |
| We believe LX9211 as a promising profile based on two completed proof-of-concept studies and a substantial market opportunity |
| We are proud of this independent recognition from ASN as we continue to study the clinical benefits of sotagliflozin, and we at Lexicon are committed to working diligently to inform broadly the scientific evidence demonstrated |
| Turning to our progress on payer coverage, we have been pleased to see coverage for INPEFA grow throughout Q3 across both commercial and Medicare formularies |
| We are pursuing market access for INPEFA across all channels, and have been able to see early access additions throughout this quarter and expect to be able to share incremental news as we move into 2024 |
| With contracted access continuing to build with large national payers, we believe that this growing clinical demand will lead to additional filled prescriptions as INPEFA achieves greater formulary coverage |
| So we do anticipate that, that will continue to grow pretty quickly, quite frankly, especially with ESI going live last week, which is a pretty major win, and we have others on the way as well |
| So as we mentioned, we're encouraged by the fact that doctors are putting pen to paper, they clearly see the value for INPEFA, and they want to try for heart failure |
| As mentioned on the prior slide, top line demand has outpaced the number of prescriptions filled with nearly 5,000 submitted claims through Q3, clearly demonstrating the impact of our field teams and customer belief and the clinical value offered by INPEFA |
| SGLT inhibitor used in heart failure has grown by 73% year-over-year through August of 2023, with the entire heart failure branded market growing by almost 40% from 2021 to 2022, representing a rapidly growing opportunity of at least $3 billion |
| The team remains laser-focused on further accelerating the positive momentum we have begun to build since launch, and helping even more patients with worsening heart failure wherever they may be cared for |
| These studies serve as evidence that INPEFA is an affordable treatment that offers important clinical value for heart failure patients and significant value for payers |
| Neuropathic pain represents a significant market opportunity |
| There remains a very good interest in LX9211 |
| As I mentioned, all the patients will be -- have the opportunity to roll over into a long-term follow-up study on drug, which allows us both to have additional data but also is a good inducement to get patients to participate in a blinded study with the placebo |
| Ex-factory shipments continued through the third quarter as wholesalers used at the initial orders received in June, a trends that we have continued to see accelerate throughout the quarter |
| Statement |
|---|
| As expected, market access has proven to be a near term restraint on early launch growth |
| Beyond the poor medical outcomes of heart failure patients, the publication also noted that acute heart failure represents one of the largest drivers of health care costs globally |
| While it is still early, the market is what we expected, both of near term challenges, coupled with substantial near and long term opportunities |
| In total, net loss for the third quarter of 2023 was $50.5 million or $0.21 per share as compared to a net loss of $23.4 million or $0.13 per share in the corresponding period in 2022 |
| Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements |
| Actually, the inventory has been drawn down quite a bit |
| If we move I think, too fast on this, then I think we will be less optimal in terms of what value we will achieve with it |
Please consider a small donation if you think this website provides you with relevant information